The owner of the internet-famous toothpaste brand "Canban" small Kuoke Technology was required to provide additional materials for its listing in Hong Kong, including whether there are issues such as favoritism.

On June 12th, the China Securities Regulatory Commission (CSRC) announced the requirements for supplementary materials for overseas issuance and listing applications. Hong Kong-based tech company Xiao Kuo Technology Co., Ltd., which is the owner of the popular toothpaste brand and oral care product "Canjian", was among the 12 companies requested to provide additional information. The company was required to explain the following matters, have them verified by lawyers, and provide clear legal opinions: 1. Explanation of the company's previous capital increases and equity transfer prices, whether there are abnormal stock prices, the presence of benefit conveyance, actual capital contributions, any failure to fulfill capital obligations, capital withdrawal, and flaws in the method of capital contribution. Conclusion on the legality and regulatory compliance of the company's establishment and previous equity changes, as well as conclusion on the company's legal entity status and valid existence. 2. Submission of explanations on pricing basis for new shareholders in the 12 months prior to the application for overseas issuance and listing, the tax payment situation of the transferor in the equity transfer process, and clear conclusions on the existence of benefit transmission. 3. Explanation of whether participants in the company's employee stock incentive plan are employees, their specific composition and positions, and whether there are any reserved or unallocated shares in the employee stock ownership platform. 4. Explanation of whether the company's and its subsidiaries' business scope and actual operations involve restricted or banned areas of foreign investment, and whether they continue to meet foreign investment access requirements after this issuance and listing and "full circulation". 5. Detailed explanation of the company's products, whether they have obtained the necessary filings, licenses, or registrations, and whether the product efficacy claims comply with legal regulations. 6. Explanation of whether the shares held by shareholders participating in "full circulation" in this issuance are pledged, frozen, or have other defects in rights.